Moses Judah Folkman ( Eng. Moses Judah Folkman , January 24, 1933 , Cleveland - January 14, 2008 , Denver ) - American cytologist , oncologist , known for his work on the theory of angiogenesis of tumors , on the basis of which in the 1990s A new generation of anti-cancer agents has been developed. The works of Folkman gave rise to an entire school of oncological research (the school of anti-angiogenesis), based on the postulate that restricting the blood supply to a tumor can slow down its development.
| Judah Folkman | |
|---|---|
| Date of Birth | |
| Place of Birth | |
| Date of death | |
| Place of death | |
| A country | |
| Place of work | |
| Alma mater | |
| Academic degree | |
| Awards and prizes |  Wolf 's Prize in Medicine (1992)  Benjamin Franklin Medal (2001) |
Content
Biography
Folkman, the son of a rabbi , was educated at Ohio State University (1953) and at Harvard University Medical School (1957), where he served most of his life. First became known in the scientific community while still a student, as a co-author of works on liver cancer surgery and pacemakers .
In the 1960s, he served as a surgeon in a civilian hospital in Massachusetts and in a military hospital near Washington . In military service, he developed a new type of implantable carrier of long-acting pharmaceuticals, on the basis of which Norplant was manufactured, and so on. At the same time, he began a focused study of the relationship between tumor growth and blood circulation. In 1967 he became the chief oncologist surgeon at the Boston Children's Hospital, Harvard University Medical School.
In 1971, Folkman first published a statement of his theory in the New England Journal of Medicine ; the scientific community took a decade to recognize it. Continuing practical experiments, his laboratory isolated the first inhibitors of angiogenesis and began clinical trials with these drugs. In the 1980s - 2000s, Folkman continued applied research at Harvard and the Children's Hospital of Boston , where he managed the vascular biology department. In total, he has published about 400 articles in reviewed medical journals and dozens of monographs in his life.
In 1992, Folkman received the Wolf Prize for the theory of angiogenesis, and public fame came to him only in 1998, when the newest anti-cancer drugs, such as Avastin , were only preparing for clinical trials. Until now, the scientific community is divided in its views on how exactly such drugs work, but most support the Folkman hypothesis.
In the last decade of his life, Folkman has been researching the course of cancer in patients with Down syndrome . People with Down syndrome, according to statistics, suffer from cancer much less frequently than mentally full people. Folkman suggested that there are areas in the genetic code of patients with Down syndrome that are responsible for the suppression of tumors, and that they can be isolated and used for the benefit of all people. These works remained unfinished. On January 14, 2008, Folkman died suddenly in the airport lounge in Denver .
Awards and honors
- Simon M. Shubitz Cancer Prize and Lectureship (1982)
- 1991 - International Gairdner Prize
- 1992 - Wolf Prize in Medicine
- 1996 -
- 1997 - Masry Prize
- 1997 -
- 1998 - John Scott Medal
- 1998 -
- 2001 - Benjamin Franklin Medal
- 2004 - Prince of Asturias Prize
- 2005 -
- 2005 - Grand Prix Lefoulon-Delalande [4]
- 2010 - introduced to the National Hall of Fame of US Inventors
Notes
- ↑ 1 2 German National Library , Berlin State Library , Bavarian State Library , etc. Record # 133892530 // Common Regulatory Control (GND) - 2012—2016.
- ↑ 1 2 Find a Grave - 1995. - ed. size: 165000000
- ↑ http://www.boston.com/news/health/blog/2008/01/research_giant.html
- ↑ Historique | Foundation Lefoulon-Delalande Institut de France
Links
- English: Obituary: Reuters
- English: Obituary: New York Times
- English: Biography at Harvard University